Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 97Lung Neoplasms 35Colorectal Neoplasms 35Pancreatic Neoplasms 13Adenocarcinoma of Lung 10Neoplasms 9Squamous Cell Carcinoma of Head and Neck 8Neoplasm Metastasis 8Head and Neck Neoplasms 8Colonic Neoplasms 7Carcinoma, Renal Cell 7Ovarian Neoplasms 6Breast Neoplasms 6Rectal Neoplasms 5Melanoma 5Endometrial Neoplasms 5Stomach Neoplasms 4Adenocarcinoma, Bronchiolo-Alveolar 4Triple Negative Breast Neoplasms 3Kidney Neoplasms 3Esophageal Neoplasms 3Uterine Cervical Neoplasms 2Urinary Bladder Neoplasms 2Thyroid Neoplasms 2Sarcoma 2Salivary Gland Neoplasms 2Recurrence 2Pleural Effusion, Malignant 2Esthesioneuroblastoma, Olfactory 2Carcinoma, Pancreatic Ductal 2

Interventions

tislelizumab 1Cetuximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Metastatic Solid Tumors × Cetuximab × Thoracic × Clear all
NCT06585488 2026-06-03

A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification

BeOne Medicines

Phase 1 Terminated
47 enrolled
GastrointestinalOther solid neoplasmThoracic

Metastatic Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡